CCAP

$13.15+0.37 (+2.90%)

Market OpenAs of Mar 17, 4:57 PM UTC

Crescent Capital BDC, Inc.

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JPMBACGS

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$13.15
Potential Upside
34%
Whystock Fair Value$17.63
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorFinancial Services
IndustryAsset Management

Crescent Capital BDC, Inc. is as a business development company is a private equity / buyouts and loan fund. It specializes in directly investing. It specializes in middle market. The fund seeks to invest in United States.

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$485.53M
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
14.14
Beta
Defensive asset. Lower volatility than the S&P 500.
0.60
Div Yield
Strong income play. Yield provides a meaningful total return floor.
1315.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
4.77%
Quick Ratio
Tight liquidity. Monitor cash flow carefully against debt.
0.56

Recent News

Zacks
Mar 10, 2026

Crescent Capital BDC (CCAP) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

After losing some value lately, a hammer chart pattern has been formed for Crescent Capital BDC (CCAP), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 2, 2026

Crescent Capital BDC (CCAP) Moves to Buy: Rationale Behind the Upgrade

Crescent Capital BDC (CCAP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 2, 2026

Down 12% in 4 Weeks, Here's Why Crescent Capital BDC (CCAP) Looks Ripe for a Turnaround

Crescent Capital BDC (CCAP) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
GuruFocus.com
Feb 26, 2026

Crescent Capital BDC Inc (CCAP) Q4 2025 Earnings Call Highlights: Strong Dividend Coverage Amid ...

Crescent Capital BDC Inc (CCAP) reports robust net investment income and a solid capital position, despite facing headwinds from unrealized losses and non-accrual increases.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
MarketBeat
Feb 26, 2026

Crescent Capital BDC Q4 Earnings Call Highlights

Crescent Capital BDC (NASDAQ:CCAP) reported fourth-quarter net investment income (NII) of $0.45 per share, down slightly from $0.46 in the prior quarter, as lower reference rates weighed on interest income. Management said results again exceeded the quarterly dividend, and the board declared a regul

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.